ClinicalTrials.govpublic full text
Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas
brain tumor, glioblastoma, gbm, interventional, phase1, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 892798
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.